Dr. Amit Kumar
interviewed in latest episode, 'The Vaccine That Could End Breast
Cancer'
SAN JOSE, Calif.,
May 6,
2024 /PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer, today announced a podcast interview of Anixa
Chairman and CEO Dr. Amit Kumar by
oncologist Dr. Sanjay Juneja, with
more than 500,000 followers through his media brand 'TheOncDoc.'
The interview is broadly available on podcast platforms and can be
viewed now on YouTube.
In the "Target: Cancer Podcast," Dr. Juneja interviews Dr. Kumar
about 'The Vaccine That Could End Breast Cancer.' The doctors
discuss the unique science behind Anixa's vaccine technology, which
enables the immune system to destroy cancer cells at the earliest
stage and prevent them from growing and spreading to surrounding
tissues and structures. Commenting on the potential for Anixa's
vaccines, Dr. Juneja stated, "It would be wonderful if we could do
for cancer what we have done for infectious diseases."
"It was a pleasure to join Dr. Juneja on his
internationally-accessed Target: Cancer Podcast channel," said Dr.
Amit Kumar. "His forum for the fight
against cancer illuminates the best ideas in cancer research that
offer the best possibilities for patients and the medical
community. I was proud to share our groundbreaking science for
cancer vaccination and the value it holds."
Dr. Sanjay Juneja is a
board-certified hematologist and medical oncologist currently
practicing in Baton Rouge,
Louisiana. Visit Dr. Juneja at sjunejamd.com and @theoncdoc
on social media platforms.
About Target: Cancer Podcast
Target: Cancer is a channel where people can learn about all the
newest technologies and treatments for cancer. Combining
technology, doctors, and patients together in a way that is
collaborative, informative, and enlightening.
The podcast was conceived and is produced by health data
innovator, xCures. The host, Dr. Juneja and guests talk about the
future of cancer treatment, addressing questions like, 'what does
that future look like?', and 'why isn't it here now?' Everyone is
terrified of cancer, but if the medical community is able to
understand it better and know how to win the battle, it's going to
give patients and doctors the assurance they desire.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple
negative breast cancer
(TNBC), the most lethal form of the disease –
as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10- Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward- looking
statements when evaluating the information presented in this press
release.
CONTACT:
Mike
Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ceo-featured-on-target-cancer-podcast-by-oncologist-dr-sanjay-juneja-302136180.html
SOURCE Anixa Biosciences, Inc.